The cell cycle and drug discovery: the promise and the hope.
暂无分享,去创建一个
[1] W. Kaelin,et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] P. Jansen-Dürr. How viral oncogenes make the cell cycle. , 1996, Trends in genetics : TIG.
[3] G. Vassal,et al. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. , 1998, Biochimie.
[4] T. Ogihara,et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[5] G. Peters,et al. Cyclin D1 and prognosis in human breast cancer , 1996, International journal of cancer.
[6] N. Dyson. The regulation of E2F by pRB-family proteins. , 1998, Genes & development.
[7] P. Guldberg,et al. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb , 1998, Leukemia.
[8] M. Lovett,et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.
[9] K. Vousden. Regulation of the cell cycle by viral oncoproteins. , 1995, Seminars in cancer biology.
[10] E J Topol,et al. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. , 1994, Circulation.
[11] C. Conti,et al. Coordinated changes in cell cycle machinery occur during keratinocyte terminal differentiation , 1999, Oncogene.
[12] G. Brooks,et al. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? , 1999, European heart journal.
[13] S. Steinberg,et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Lippman,et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[16] A. Cribier,et al. Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. , 1998, Journal of the American College of Cardiology.
[17] A. Hengstermann,et al. Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells , 1998, Journal of Virology.
[18] E. Lakatta,et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. , 1995, The Journal of clinical investigation.
[19] W. Zwerschke,et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. , 1996, Oncogene.
[20] L. Meijer,et al. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. , 1997, Experimental cell research.
[21] W. Hong,et al. Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.
[22] T. Jacks,et al. Tumor Induction and Tissue Atrophy in Mice Lacking E2F-1 , 1996, Cell.
[23] Y. Furukawa,et al. Over‐expression and amplification of the CDC2 gene in leukaemia cells , 1995, British journal of haematology.
[24] K. Münger,et al. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. , 1997, Genes & development.
[25] N. Matsubara,et al. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. , 1997, Cancer research.
[26] J. Nevins,et al. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[27] P. Nurse,et al. Animal cell cycles and their control. , 1992, Annual review of biochemistry.
[28] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[29] J. Graybill. The future of antifungal therapy. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] T. Jacobs,et al. Cell Cycle Control , 1995 .
[31] A. Levitzki,et al. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. , 1998, Experimental cell research.
[32] R. Buckle,et al. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. , 1998, Genes & development.
[33] K. Manova-Todorova,et al. Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.
[34] Y. Chen,et al. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. , 1991, Oncogene.
[35] A. Levitzki. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] G. Stamp,et al. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. , 1995, Genes & development.
[37] J. Seltzer,et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product , 1995, Science.
[38] L. Hartwell,et al. Cell cycle control and cancer. , 1994, Science.
[39] N. L. Thangue,et al. DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. , 1994 .
[40] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[41] P. Nurse. Checkpoint Pathways Come of Age , 1997, Cell.
[42] N. L. Thangue,et al. Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor , 1997, Nature Biotechnology.
[43] B. Nickoloff,et al. Differential expression of cell survival and cell cycle regulatory proteins in cutaneous squamoproliferative lesions. , 1999, Journal of dermatological science.
[44] P. Tsao,et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. , 1997, The Journal of clinical investigation.
[45] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[46] J. A. Hamilton,et al. Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.
[47] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[48] Emma Lees,et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.
[49] A. Levitzki,et al. Tyrphostin AG 494 blocks Cdk2 activation , 1997, FEBS letters.
[50] Nobuyuki Shishido,et al. Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.
[51] E. White,et al. Life, death, and the pursuit of apoptosis. , 1996, Genes & development.
[52] Y. Kaneda,et al. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. , 1998, Circulation research.
[53] E. Nabel,et al. Expression of cyclin-dependent kinase inhibitors in vascular disease. , 1998, Circulation research.
[54] Jian-Mei Li,et al. Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. , 1998, Cardiovascular research.
[55] A. Bradley,et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis , 1992, Nature.
[56] T. Ogihara,et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[57] M. Wall,et al. Camptothecin and taxol: Discovery to clinic , 1998, Medicinal research reviews.
[58] D. Schrijvers,et al. Update on the taxoids and other new agents in head and neck cancer therapy. , 1998, Current opinion in oncology.
[59] L. Meijer,et al. Chemical inhibitors of cyclin-dependent kinases , 1997 .
[60] K. Vousden,et al. Transcriptional activation by p53 correlates with suppression of growth but not transformation , 1994, Cell.
[61] M. Aoki,et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide , 1997, Nature Medicine.
[62] James M. Roberts,et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.
[63] G. Bevilacqua,et al. Cyclin‐D1 expression in node‐positive (N+) and node‐negative (N−) infiltrating human mammary carcinomas , 1999, International journal of cancer.
[64] P. Tsao,et al. Genetic engineering of vein grafts resistant to atherosclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[65] S. Morris. Molecular clocks: Defusing the Cambrian ‘explosion’? , 1997, Current Biology.
[66] P. V. van Diest,et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. , 1997, The American journal of pathology.
[67] N. Kashihara,et al. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. , 1998, The Journal of clinical investigation.
[68] T. Ogihara,et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. , 1994, The Journal of clinical investigation.
[69] E. Fearon. Human cancer syndromes: clues to the origin and nature of cancer. , 1997, Science.
[70] Anthony R. Hall,et al. p53-dependent cell death/apoptosis is required for a productive adenovirus infection , 1998, Nature Medicine.
[71] K. Kinzler,et al. Sequence-specific transcriptional activation is essential for growth suppression by p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[72] N. L. La Thangue,et al. A new component of the transcription factor DRTF1/E2F , 1993, Nature.
[73] Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 , 1997, Current Biology.
[74] M. Greenberg,et al. E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation , 1996, Cell.
[75] L. Chin,et al. Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.
[76] D. Kirn,et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.
[77] J. Gabrilove,et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. , 1997, Blood.
[78] H. Hausen. Human papillomaviruses in the pathogenesis of anogenital cancer. , 1991 .
[79] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[80] C. Prives,et al. p53: puzzle and paradigm. , 1996, Genes & development.
[81] J. Nevins,et al. Expression of transcription factor E2F1 induces quiescent cells to enter S phase , 1993, Nature.
[82] J. Pines,et al. Cyclins and cyclin-dependent kinases: take your partners , 1993 .
[83] B. Stillman,et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. , 1997, Genes & development.
[84] J. Leiden,et al. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. , 1995, The Journal of clinical investigation.
[85] Antonio Colombo,et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.
[86] James M. Roberts,et al. A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.